查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1517292

CDK2 抑制剂市场 – 管道分析（2024）

CDK2 Inhibitor - Pipeline Analytics 2024
出版日期: | 出版商: Mellalta Meets LLP | 英文 114 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

细胞週期蛋白依赖性激酶 2（CDK2）是控制细胞分裂和细胞週期的重要蛋白激酶。 CDK2 失调与多种癌症有关，使其成为治疗干预的有吸引力的目标。

CDK2 抑制剂代表了一个有吸引力的投资机会。这些抑制剂针对关键的细胞週期动态，为多种高负担癌症类型（包括乳癌和卵巢癌）提供治疗潜力。

CDK2 抑制剂市场充满活力，竞争激烈，Sino Biopharma、Tiziana Life Sciences、Incyclix Bio、Pfizer、Cyclacel Pharmaceuticals、Blueprint Medicines等主要公司提供超过 36 种产品。这些公司研究 CDK2 抑制剂的各种适应症，包括 ER+/HER2 乳癌、非小细胞肺癌、去分化脂肪肉瘤、卵巢癌、不可切除/转移性肝细胞癌和 CCNE1 扩增癌症。

凭藉强大的产品线和有前景的临床资料，这些抑制剂代表了肿瘤学领域的高回报机会。许多具有CDK2抑制活性的小分子抑制剂已被鑑定。然而，这些抑制剂的开发充满了挑战，特别是由于细胞週期蛋白依赖性激酶（CDK）之间的结构相似性而导致的特异性。

CDK2抑制剂市场竞争激烈，有超过36种抑制剂。大部分处于早期阶段，其中探索阶段占38.89%，临床前阶段占19.44%，第一期产品占19.44%。 %。

在主要进入者中，Blueprint Medicines 和辉瑞拥有最多的资产，共有三个投资组合。

本报告调查了全球 CDK2 抑制剂市场，并提供了市场现状、病例量趋势、患者趋势、竞争产品市场定位和市场机会。

目录

第1章 概述

第2章 CDK2抑制剂的标靶背景

  • CDK2抑制剂的介绍与作用
  • 对 CDK4/6 抑制剂的潜在担忧
  • CDK2抑制剂：肿瘤学中极具前景的标靶
  • CDK2抑制剂的临床应用
  • 克服 CDK4/6 抗药性：CDK2 抑制剂的策略作用
  • CDK2抑制剂的变构机制

第3章 CDK2抑制剂管线的阶段特异性分析

  • CDK2 抑制剂的开发 - 概述
  • 依开发阶段划分的管道产品
  • 各公司的管道产品
  • 依适应症和阶段划分的管道产品
  • CDK2抑制剂单药及合併治疗的临床试验
  • CDK2管道：临床试验的地理分布
  • CDK2 抑制剂的临床和监管时间表
  • 后期概况比较概述

第4章 CDK2 抑制剂授权、收购与合作协议

  • CDK2 抑制剂的授权、收购与交易价值
  • CDK2抑制剂许可交易类型和总规模

第5章 CDK2抑制剂管线状况

  • CDK2 抑制剂研发管线的药物概况 - 概述
    • 第三期
    • 第二期
    • 第一/二期
    • 第一期
    • 临床前
    • 药物发现

第6章 变构 CDK2 抑制剂的机制 - 概述

第7章 CDK2抑制剂的SWOT分析

第8章 附录

简介目录

The 2024 Mellalta Meets report analyzes the CDK2 inhibitor pipeline landscape, highlighting the market opportunities and competitive landscape with over 32 companies developing pipeline drug profiles.

Cyclin-dependent kinase 2 (CDK2) is a pivotal protein kinase that orchestrates cell division and the cell cycle. Dysregulation of CDK2 has been implicated in various cancers, making it an attractive target for therapeutic intervention.

CDK2 inhibitors present a compelling investment opportunity. These inhibitors target critical cell cycle dynamics, offering therapeutic potential across multiple high-burden cancer types such as Breast and Ovarian Cancer.

The CDK2 inhibitor market is highly dynamic and competitive with over 36 products with key players, including Sino Biopharma, Tiziana Life Sciences, Incyclix Bio, Pfizer, Cyclacel Pharmaceuticals, and Blueprint Medicines. These companies are pursuing various indications for CDK2 inhibitors, such as ER+/HER2- breast cancer, non-small cell lung cancer, dedifferentiated liposarcoma, ovarian cancer, unresectable/metastatic hepatocellular carcinoma, and CCNE1-amplified cancers.

With a robust pipeline and promising clinical data, these inhibitors represent a high-reward opportunity in the oncology landscape. Numerous small molecule inhibitors have been identified for their CDK2 inhibitory activity. However, the development of these inhibitors is fraught with challenges, particularly regarding specificity due to the structural similarities among cyclin-dependent kinases (CDKs).

Efforts are ongoing to engineer inhibitors that selectively target CDK2, thereby minimizing off-target effects and enhancing therapeutic efficacy. As research progresses, CDK2 inhibitors are poised to play a transformative role in overcoming CDK4/6 resistance, offering significant benefits for patients and lucrative opportunities for investors with the usage of different CDK2 targeting strategies such as protein-protein interaction, Allosteric, Orthosteric, and indirect inhibition.

The CDK2 Inhibitor - Pipeline Analytics -2024 report published by Mellalta Meets covers the Cell Therapies market opportunity providing Key Competitive Analysis, 32+ Companies and 36 Products with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports cover pipeline product analysis by stage of development, competitive landscape by phases, companies, clinical trials by regions, and intervention type. CDK2 Inhibitor-Pipeline Analytics report adds value in terms of describing clinical-stage products for their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

Mellalta's CDK2 Inhibitor Pipeline Report - Key Highlights

The CDK2 inhibitors market is highly competitive, with over 36 inhibitors. The majority are in the early stage, with 38.89% in the Discovery stage, 19.44% in the pre-clinical stage, and 19.44% in Phase 1. Phase 1/2 products make up 16.67% of the total, while Phase 3 and Phase 2 products each represent 2.78%.

Among the key players, Blueprint Medicines and Pfizer stand out with the highest number of assets, totaling three in its portfolio.

Allosteric inhibitors are favored and preferred mechanisms due to their low toxicity profiles.

Cyclins are being directly targeted as a focused approach to avoid toxicity.

Report Coverage:

Indication Prioritization: CDK2 Inhibitor market potential

Business Transactions & Strategies: Key collaborations and deal values

CDK2 Inhibitor Pipeline Development: Product Profiles, Clinical Trials & Results

CDK2 Inhibitor Acquisition Targets

CDK2 Inhibitor Competitive Intelligence

Recent and upcoming events

Table of Content

1. OVERVIEW

2. The CDK2 Inhibitor Target BACKGROUND

  • 2.1. Introduction and Role of CDK2 inhibitors
  • 2.2. Potential Concern with CDK4/6 Inhibitors
  • 2.3. CDK2 Inhibitors: A Highly-Potential Target in Oncology Space
  • 2.4. Clinical Applications of CDK2 Inhibitors
  • 2.5. Overcoming CDK4/6 Resistance: The Strategic Role of CDK2 Inhibitors
  • 2.6. Allosteric Mechanism of CDK2 Inhibitors

3. CDK2 Inhibitor PIPELINE ANALYSIS by Phases

  • 3.1. CDK2 Inhibitor Development - Overview
  • 3.2. Pipeline Products by Stage of Development
  • 3.3. Pipeline Products by Company
  • 3.4. Pipeline Products by Indication and Phases
  • 3.5. CDK2 Inhibitor Monotherapy & Combinations Clinical Trials
  • 3.6. CDK2 Pipeline: Geographic Distribution of Clinical Trials
  • 3.7. CDK2 Inhibitor Clinical & Regulatory Timelines
  • 3.8. Late-Stage Profiles Comparisons At-a-glance

4. CDK2 Inhibitor LICENSING, ACQUISITION, AND COLLABORATION DEALS

  • 4.1. CDK2 Inhibitor Licensing, Acquisition, and Deal values
  • 4.2. CDK2 Inhibitor Licensing by Transaction type and total amount size by Phases

5. CDK2 Inhibitor Pipeline Landscape

  • 5.1. CDK2 Inhibitor Pipeline Drug Profiles- at a glance
    • 5.1.1. Phase III
      • 5.1.1.1. TQB3616 (Sino Biopharma)
        • 5.1.1.1.1. Product Profile & Description
        • 5.1.1.1.2. Clinical Trials
        • 5.1.1.1.3. Collaborations
        • 5.1.1.1.4. Other Developments
    • 5.1.2. Phase II
      • 5.1.2.1. Milciclib (Tiziana Life Sciences)
        • 5.1.2.1.1. Product Profile & Description
        • 5.1.2.1.2. Clinical Trials
        • 5.1.2.1.3. Collaborations
        • 5.1.2.1.4. Other Developments
    • 5.1.3. Phase I/II
      • 5.1.3.1. INX-315 (Incyclix Bio)
        • 5.1.3.1.1. Product Profile & Description
        • 5.1.3.1.2. Clinical Trials
        • 5.1.3.1.3. Collaborations
        • 5.1.3.1.4. Other Developments
      • 5.1.3.2. Fadraciclib (Cyclacel Pharmaceuticals)
        • 5.1.3.2.1. Product Profile & Description
        • 5.1.3.2.2. Clinical Trials
        • 5.1.3.2.3. Collaborations
        • 5.1.3.2.4. Other Developments
      • 5.1.3.3. PF 07104091 (Pfizer)
        • 5.1.3.3.1. Product Profile & Description
        • 5.1.3.3.2. Clinical Trials
        • 5.1.3.3.3. Collaborations
        • 5.1.3.3.4. Other Developments
      • 5.1.3.4. AVZO-021 (Avenzo Therapeutics/Allorion Therapeutics Inc)
        • 5.1.3.4.1. Product Profile & Description
        • 5.1.3.4.2. Clinical Trials
        • 5.1.3.4.3. Collaborations
        • 5.1.3.4.4. Other Developments
      • 5.1.3.5. AZD 8421 (AstraZeneca)
        • 5.1.3.5.1. Product Profile & Description
        • 5.1.3.5.2. Clinical Trials
        • 5.1.3.5.3. Collaborations
        • 5.1.3.5.4. Other Developments
      • 5.1.3.6. BLU 222 (Blueprint Medicines)
        • 5.1.3.6.1. Product Profile & Description
        • 5.1.3.6.2. Clinical Trials
        • 5.1.3.6.3. Collaborations
        • 5.1.3.6.4. Other Developments
    • 5.1.4. Phase I
      • 5.1.4.1. NKT 3447 (NiKang Therapeutics)
        • 5.1.4.1.1. Product Profile & Description
        • 5.1.4.1.2. Clinical Trials
        • 5.1.4.1.3. Collaborations
        • 5.1.4.1.4. Other Developments
      • 5.1.4.2. BG-68501 (BeiGene)
        • 5.1.4.2.1. Product Profile & Description
        • 5.1.4.2.2. Clinical Trials
        • 5.1.4.2.3. Collaborations
        • 5.1.4.2.4. Other Developments
      • 5.1.4.3. TYK 0540 (TYK Medicine)
        • 5.1.4.3.1. Product Profile & Description
        • 5.1.4.3.2. Clinical Trials
        • 5.1.4.3.3. Collaborations
        • 5.1.4.3.4. Other Developments
      • 5.1.4.4. INCB123667 (Incyte)
        • 5.1.4.4.1. Product Profile & Description
        • 5.1.4.4.2. Clinical Trials
        • 5.1.4.4.3. Collaborations
        • 5.1.4.4.4. Other Developments
      • 5.1.4.5. RGT-419B (REGOR THERAPEUTICS)
        • 5.1.4.5.1. Product Profile & Description
        • 5.1.4.5.2. Clinical Trials
        • 5.1.4.5.3. Collaborations
        • 5.1.4.5.4. Other Developments
      • 5.1.4.6. SYH2043 (CSPC Ouyi Pharmaceutical)
        • 5.1.4.6.1. Product Profile & Description
        • 5.1.4.6.2. Clinical Trials
        • 5.1.4.6.3. Collaborations
        • 5.1.4.6.4. Other Developments
      • 5.1.4.7. WXWH0240 (Cisen Pharmaceutical)
        • 5.1.4.7.1. Product Profile & Description
        • 5.1.4.7.2. Clinical Trials
        • 5.1.4.7.3. Collaborations
        • 5.1.4.7.4. Other Developments
    • 5.1.5. Preclinical
      • 5.1.5.1. IAM-C1 (Iambic Therapeutics)
        • 5.1.5.1.1. Product Profile & Description
        • 5.1.5.1.2. Collaborations
        • 5.1.5.1.3. Other Developments
      • 5.1.5.2. AU14-5 (AUCENTRA)
        • 5.1.5.2.1. Product Profile & Description
        • 5.1.5.2.2. Collaborations
        • 5.1.5.2.3. Other Developments
      • 5.1.5.3. CID-078 (Circle Pharma)
        • 5.1.5.3.1. Product Profile & Description
        • 5.1.5.3.2. Collaborations
        • 5.1.5.3.3. Other Developments
      • 5.1.5.4. CC002 (Chupu Chuangzhi (Wuhan) Pharmaceutical Technology)
        • 5.1.5.4.1. Product Profile & Description
        • 5.1.5.4.2. Collaborations
        • 5.1.5.4.3. Other Developments
      • 5.1.5.5. IpY.20 (Concarlo Therapeutics)
        • 5.1.5.5.1. Product Profile & Description
        • 5.1.5.5.2. Collaborations
        • 5.1.5.5.3. Other Developments
      • 5.1.5.6. CED-2368 (Bayer)
        • 5.1.5.6.1. Product Profile & Description
        • 5.1.5.6.2. Collaborations
        • 5.1.5.6.3. Other Developments
      • 5.1.5.7. TY-1210 (TYK Medicines)
        • 5.1.5.7.1. Product Profile & Description
        • 5.1.5.7.2. Collaborations
        • 5.1.5.7.3. Other Developments
    • 5.1.6. Discovery
      • 5.1.6.1. CDK2 and CCNE1 (Kymera Therapeutics)
        • 5.1.6.1.1. Product Profile & Description
        • 5.1.6.1.2. Collaborations
        • 5.1.6.1.3. Other Developments
      • 5.1.6.2. CDK2 targeting therapeutics (Plexium)
        • 5.1.6.2.1. Product Profile & Description
        • 5.1.6.2.2. Collaborations
        • 5.1.6.2.3. Other Developments
      • 5.1.6.3. CDK2 Inhibitor (Bugworks)
        • 5.1.6.3.1. Product Profile & Description
        • 5.1.6.3.2. Collaborations
        • 5.1.6.3.3. Other Developments
      • 5.1.6.4. CDK2 degraders (Monte Rosa Therapeutics)
        • 5.1.6.4.1. Product Profile & Description
        • 5.1.6.4.2. Collaborations & Other Developments
      • 5.1.6.5. BLU-956 (Blueprint Medicines)
        • 5.1.6.5.1. Product Profile & Description
        • 5.1.6.5.2. Collaborations
        • 5.1.6.5.3. Other Developments
      • 5.1.6.6. TPD: CDK2 (Blueprint Medicines)
        • 5.1.6.6.1. Product Profile & Description
        • 5.1.6.6.2. Collaborations
        • 5.1.6.6.3. Other Developments
      • 5.1.6.7. QR-6401 (REGOR THERAPEUTICS)
        • 5.1.6.7.1. Product Profile & Description
        • 5.1.6.7.2. Collaborations
        • 5.1.6.7.3. Other Developments
      • 5.1.6.8. CDK2 inhibitor (Calibr-Skaggs)
        • 5.1.6.8.1. Product Profile & Description
        • 5.1.6.8.2. Collaborations
        • 5.1.6.8.3. Other Developments
      • 5.1.6.9. Cyclin E/CDK2 inhibitor (Circle Pharma)
        • 5.1.6.9.1. Product Profile & Description
        • 5.1.6.9.2. Collaborations
        • 5.1.6.9.3. Other Developments
      • 5.1.6.10. TMX-2172 (Dana-Farber Cancer Institute)
        • 5.1.6.10.1. Product Profile & Description
        • 5.1.6.10.2. Collaborations
        • 5.1.6.10.3. Other Developments
      • 5.1.6.11. CDK2 Inhibitor (Acellera Therapeutics)
        • 5.1.6.11.1. Product Profile & Description
        • 5.1.6.11.2. Collaborations
        • 5.1.6.11.3. Other Developments
      • 5.1.6.12. FP19711 and FP24322 (Fog Pharma)
        • 5.1.6.12.1. Product Profile & Description
        • 5.1.6.12.2. Collaborations
        • 5.1.6.12.3. Other Developments
      • 5.1.6.13. I-125A and I-198 (Pfizer/ Belharra Therapeutics/ Magnet Biomedicine)
        • 5.1.6.13.1. Product Profile & Description
        • 5.1.6.13.2. Collaborations
        • 5.1.6.13.3. Other Developments

6. Allosteric CDK2 Inhibitor Mechanisms- At a glance

7. CDK2 Inhibitor SWOT Analysis

8. Appendix